Genovia: exosomes without the cold chain.
Adipose-derived stem cell exosomes for topical aesthetic use — roughly 2 billion per mL, freeze-dried at −80 °C and shipped dry. A different company, a different category and a different regulatory posture to the therapeutic biologics on our biologics page.
- Category
- Topical cosmetic preparation. Approximately 2 billion adipose-derived stem cell exosomes per mL, used topically and never injected.
- Manufacturer
- BioGenomics. Genovia is manufactured by BioGenomics; Eventide is a distributor, not the manufacturer.
- Regulatory
- Genovia is manufactured by BioGenomics in a facility the company states complies with FDA, KFDA and GMP standards. A facility standard describes how a product is made; it is not an approval of the product. The statement that closes this page governs the product itself.
- What it costs
- Quoted per order. Product documentation and certificates are supplied with each order — ask and we will send a sample set before you commit.
Genovia is not ZEO, and the difference matters
Both lines are exosome products and both come through Eventide, but they are made by different companies for different purposes, and they sit in different regulatory categories. Conflating them is the most common mistake we see clinics make.
Practices with a topical procedure menu
- You already run microneedling, RF microneedling, laser resurfacing or other post-procedure protocols and want a topical to pair with them.
- You are outside Florida, Utah, Georgia and Tennessee, where the therapeutic biologics lines are available.
- You do not want a freezer, a cold-chain courier or a shipping window in the treatment room.
- Your medical director wants product documentation and certificates in hand before the first order.
What a topical cosmetic preparation is not
- Topical only — not injected. A protocol that calls for an injectable exosome is the other line: a different manufacturer, a different product and a different regulatory category.
- It is a topical cosmetic preparation, not a drug. The statement that closes this page governs how it may be described.
- The published record is in-vitro. Cell and tissue models are not clinical trials in patients, and no result for any person follows from them.
- A facility that a company states meets FDA, KFDA and GMP standards is a manufacturing posture, not a clearance or an approval for the product made in it.
Read the other way, that legibility is the appeal: a topical cosmetic preparation sits outside the state-by-state gating that governs the injectable line, and it can be described accurately in a single sentence every time it is described.
Four questions worth asking us
- Which documentation and certificates come with the order, and can I see a sample set first?
- What does the facility standards statement actually cover, and what does it leave open?
- Which of the in-vitro figures relate to the procedures I already run?
- What does a vial cost at the volume one treatment room will use in a month?
How the yield problem gets solved
Only about 0.1% of stem cell culture media is exosomes, so producing them at concentration usually means repeatedly subculturing large volumes of cells — and every passage degrades the cells and the exosomes they make.
- Exosome load
- Approximately 2 billion exosomes per mL, in a vial.
- Source
- Adipose-derived stem cells.
- Stabilisers
- Sodium hyaluronate and trehalose.
- Drying and storage
- Cryogenically freeze-dried at −80 °C, so it ships and stores without a cold chain.
- Route
- Topical only — not injected. Providers use it alongside microneedling, RF microneedling, laser resurfacing and other post-procedure protocols.
A natural stimulant, not more passages
Step oneA patented culture step uses a natural stimulant that the manufacturer cites as raising exosome secretion more than fourfold, which keeps passage numbers low and cell health high.
Filtration and characterisation
Step two0.2 µm precision filtration, then nanoparticle tracking analysis and immunoblotting to characterise what is actually in the vial.
Freeze-dried at −80 °C
Step threeCryogenic freeze-drying with sodium hyaluronate and trehalose as stabilisers — which is why it ships and stores without refrigeration.
What is in the vesicle
Step fourExosomes are 30–150 nm vesicles carrying RNA, proteins and lipids, including growth factors, mRNA and miRNA.
| What differs | Genovia by BioGenomics | ZEO ScientifiX |
|---|---|---|
| Category | Topical cosmetic preparation | Perinatal and autologous biologics |
| Route | Topical only — not injected | Therapeutic protocols in designated states |
| Source | Adipose-derived stem cells | Umbilical cord, amniotic, autologous platelets |
| Where it fits | Microneedling, RF, laser, post-procedure | Orthopedic, pain, wound care, aesthetics |
| Storage | Freeze-dried, no cold chain | Cryopreserved and lyophilised formats |
| Availability | All 50 states | FL, UT, GA and TN |
The manufacturer's in-vitro testing
Published by BioGenomics and reproduced here so you can evaluate it yourself. These are in-vitro laboratory studies — cell and tissue models, not clinical trials in patients. They describe how the material behaved in a lab, and they are not a claim about results for any person.
| Source | What it says | What it does not establish |
|---|---|---|
| Manufacturer in-vitro studies | Six laboratory figures published by BioGenomics, reproduced in full below: skin penetration, human dermal fibroblast proliferation, elastin retention under SDS stress, pro-collagen and fibrolectin activity, keratinocyte aggregation and dermal papilla markers. | Cell and tissue models, not clinical trials in patients. They describe how the material behaved in a lab, and they are not a claim about results for any person. |
| Patented culture step | A patented culture step uses a natural stimulant that the manufacturer cites as raising exosome secretion more than fourfold, which keeps passage numbers low and cell health high. | A secretion-yield figure is a manufacturing measure taken upstream of the vial. It says nothing about what the finished preparation does on skin. |
| Filtration and characterisation | 0.2 µm precision filtration, then nanoparticle tracking analysis and immunoblotting to characterise what is actually in the vial. | Characterisation establishes what is in the vial. A particle count and a protein blot are identity and content, not effect. |
| Manufacturing facility | Genovia is manufactured by BioGenomics in a facility the company states complies with FDA, KFDA and GMP standards. | A facility standard describes how the product is made. It is not an approval, a clearance or a registration of the product itself, and it names no indication. |
The six figures below are the manufacturer's own, reproduced so you can read them yourself rather than take a summary of them. Nothing here claims a result for any patient.
What pathway a topical cosmetic preparation is actually on
Genovia’s category is not a weaker version of the injectable one. It is a different pathway with a different rulebook, and the rulebook has been rewritten more recently than most of this industry has noticed.
- No premarket approval — by design, not by omission
- Under the FD&C Act, cosmetic products and ingredients, with the exception of colour additives, require no FDA approval before they go on the market. That is the statute working as written. It is also why no honest supplier can hand you an approval letter for a cosmetic: there is no letter to hand you.
- MoCRA built the structure that was missing
- The Modernization of Cosmetics Regulation Act of 2022 (P.L. 117-328) is the largest expansion of cosmetics oversight since 1938. Facilities register, products are listed, safety substantiation must be kept on file, serious adverse events must be reported, and the FDA now holds mandatory recall authority. Registration and listing are a pathway, not a credential: the FDA calls them “neither a cosmetic approval program nor a promotional tool,” and issues no certificates for either. A supplier waving “FDA-registered” as a quality badge is using the phrase in the one way the FDA has said not to.
- Intended use is what decides the category
- Whether a topical is a cosmetic or a drug is settled by intended use, which the FDA establishes from the claims made on the label, in advertising, on a website and in social posts. A product does not become a drug because of what is in it; it becomes a drug because of what is said about it. Appearance is a cosmetic claim. Repair, regeneration, healing and inflammation are not — and a single caption can move a product from one category to the other for everyone selling it.
- Where this leaves an operator
- It leaves you with a product you can put on the menu in all fifty states, describe accurately in one sentence, and defend without a lawyer in the room — provided the sentence stays about appearance. Practices building around regenerative, longevity and performance medicine are getting more room to work in every year; the discipline of saying exactly what a product is, and nothing more, is what keeps that room open.
Sources for this section: FD&C Act §§201(g) and 201(i); FDA, Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?); FDA, Modernization of Cosmetics Regulation Act of 2022. Read as of 7 August 2026 and reviewed on the 90-day compliance interval. General regulatory information for licensed providers, not legal advice.
Enhanced skin penetration
Fluorescent-marked Genovia exosomes shown penetrating into the dermis at a higher rate than the comparator exosomes in the same test.
Human dermal fibroblast proliferation
Greater than 30% proliferation of human dermal fibroblasts compared with control, and compared against vitamin C and empty exosome particles.
Skin elastin retention
Retention of the skin barrier in the presence of SDS, an oxidant chemical used to stress the barrier in vitro.
Regeneration and elasticity
In vitro testing of Genovia's effect on the activity of pro-collagen type I, elastin and fibrolectin.
Barrier strengthening and moisturising
Aggregation of keratinocytes in the presence of exosomes, which strengthens the skin barrier and helps skin stay hydrated.
Dermal papilla and hair-cycle markers
Dermal papilla cells, hair germ and bulge stem-cell activity, which determine the growth stage of hair.
Buying Genovia in the US
Genovia is manufactured by BioGenomics in a facility the company states complies with FDA, KFDA and GMP standards. Eventide Aesthetics & Wellness supplies it to licensed providers and practice owners.
we are the distributor here, not the manufacturer.
- A US distributor, not the manufacturer
- We handle supply, documentation and support. Manufacturing, testing and product specifications are BioGenomics'.
- All 50 states
- Topical cosmetic supply is not subject to the state restrictions that apply to the therapeutic biologics lines. Closest, in-person coverage across the Southeast.
- Licensed providers and practice owners
- Business-to-business only. Nothing on this page is directed to patients.
- Documentation with every order
- Product documentation and certificates are supplied with each order — ask and we will send a sample set before you commit.
What providers ask about Genovia
What is Genovia?
A topical exosome preparation from BioGenomics, made from adipose-derived stem cells. Each vial carries approximately 2 billion exosomes per mL, stabilised with sodium hyaluronate and trehalose and cryogenically freeze-dried at −80 °C, so it ships and stores without a cold chain.
Is Genovia the same company as ZEO ScientifiX?
No. Genovia is made by BioGenomics and is a topical cosmetic preparation for aesthetic use. ZEO ScientifiX is a separate company supplying perinatal and autologous biologics for therapeutic protocols in designated states. Eventide supplies both, but they are different manufacturers, different products and different regulatory categories.
How is Genovia used in a clinic?
Providers use it topically, typically alongside microneedling, RF microneedling, laser resurfacing and other post-procedure protocols. It is a topical cosmetic preparation; it is not injected and is not intended to treat disease.
Who supplies Genovia in the United States?
Eventide Aesthetics & Wellness supplies Genovia to licensed providers and practice owners across all 50 US states, with closest coverage across the Southeast. Genovia is manufactured by BioGenomics; Eventide is a distributor, not the manufacturer.
Reviewed 24 July 2026 by Justin Messner, Co-Founder, Eventide Aesthetics & Wellness.
Read these as lab data, not outcomes. Genovia is a topical cosmetic preparation. It is not FDA-approved, it is not a drug, and it is not intended to diagnose, treat, cure or prevent any disease or condition — including hair loss. The figures above are the manufacturer's in-vitro results in cell and tissue models. No patient outcome is claimed or guaranteed. For licensed medical providers and practice owners; not directed to patients.